Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Metformin is a widely used antidiabetic agent for obesity-related type 2 diabetes mellitus, providing significant health benefits such as reduced blood glucose levels and body weight. Emerging evidence suggests that metformin may play a beneficial role in delaying aging. However, the causal relationship between metformin use and frailty index (FI) remains uncertain and warrants further investigation. This study aimed to explore the genetically predicted causal relationship between metformin targets and FI.
Methods: A two-sample Mendelian randomization (MR) analysis was conducted. Genetic proxies for the target effects of metformin were identified as single nucleotide polymorphisms (SNPs) associated with body weight and corresponding gene expression levels. Summary statistics for the FI were obtained from the genome-wide association study (GWAS) meta-analysis. Additionally, a two-step MR approach was employed to explore whether glycated haemoglobin (HbA1c) exhibits a mediating effect on the relationship between body weight and frailty risk. In the MR analysis, the inverse variance weighted method served as the primary analytical approach, supplemented by sensitivity analyses.
Results: A total of 10 SNPs were included as genetic predictors of metformin. The average effect of the genetic proxies for metformin targets, equivalent to a 1 standard deviation reduction in body weight, was associated with a reduced FI (β: -0.41, 95% CI: -0.74 to -0.07, P = 0.017). Notably, weight reduction induced by the target Mitochondrial complex I (MCI) showed a role in reducing FI. Furthermore, HbA1c mediated 5.5% of the total effect of body weight on FI.
Conclusions: The findings of this study support the notion that metformin may reduce frailty risk through the target MCI, with this effect potentially being partially attributable to weight reduction. These findings provide new insights for developing therapeutic strategies targeting aging and frailty prevention.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12183837 | PMC |
| http://dx.doi.org/10.1186/s13098-025-01825-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploratory Assessment of Preoperative GLP-1 Receptor Agonists Before Sleeve Gastrectomy: A Retrospective Matched Analysis.
Obes Surg
September 2025
Clinique Mutualiste de Pessac, Pessac, France.
Background: Preoperative treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) before bariatric surgery has not been studied. Therefore, we investigated the impact of neoadjuvant treatment with GLP-1 RAs on weight loss and postoperative outcomes in patients who underwent sleeve gastrectomy for severe obesity.
Method: A retrospective single-center study was conducted between January 2022 and December 2023.
Using obesity management medications within the first year after laparoscopic sleeve gastrectomy may enhance weight-loss outcomes.
Obes Surg
September 2025
E-Da Hospital, Kaohsiung City, Taiwan.
Background: We retrospectively evaluated the efficacy of using additional obesity management medications (OMMs) within the first year after undergoing laparoscopic sleeve gastrectomy (LSG).
Methods: We retrospectively analyzed 246 patients who underwent primary LSG in our institution and were followed up for at least 12 months. We collected body weights preoperatively and at three, six, 12, and 24 months postoperatively, along with body composition and laboratory results preoperatively and at 12 months.
Algorithm to detect ISUP ≥ 2 prostate cancer using canine detection.
World J Urol
September 2025
Bichat Claude Bernard Hospital, Public Assistance of Paris Hospitals, Paris, France.
Purpose: Screening and diagnosing ISUP ≥ 2 prostate cancer is challenging. This study aimed to determine whether canine detection could be beneficial addition to the ISUP ≥ 2 prostate cancer diagnostic protocol by creating a decision-making algorithm for men with suspected prostate cancer.
Methods: We conducted a prospective study at two urology institutions and a French veterinary school, including men with a suspicion of prostate cancer from November to April 2023, which were divided into two groups according to their prostate biopsy results.
Association between the English National Health Service Diabetes Prevention Programme and incident multiple long-term conditions.
Nat Med
September 2025
Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
Existing evaluations of the National Health Service Diabetes Prevention Programme (NHS DPP) in England have demonstrated associated reductions in body weight, hemoglobin A1c and incident type 2 diabetes (T2D). In this study, we examined associations between completion of the NHS DPP and incidence of T2D and 30 other long-term conditions (LTCs), including LTCs considered linked to the program's interventional goals of body weight reduction, increased physical activity and improved diet quality (LTC-L) and LTCs considered to be possibly linked to those goals (LTC-PL). We found that completers of the NHS DPP had lower incidences of T2D, LTC-L and LTC-PL compared to non-attenders.
View Article and Find Full Text PDFAssociation of intraoperative end-tidal CO levels with postoperative outcomes: a patient-level analysis of two randomised clinical trials.
Br J Anaesth
September 2025
Department of Anaesthesiology, Amsterdam University Medical Centers, location 'AMC', Amsterdam, The Netherlands; Department of Anaesthesiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Background: The relationship between intraoperative end-tidal CO (etCO) levels and postoperative outcomes remains unclear. We conducted a post hoc analysis of two randomised trials in adults undergoing major surgery under general anaesthesia.
Methods: We re-analysed individual participant data comparing high or low positive end-expiratory pressure with low tidal volume intraoperative ventilation using a merged database derived from two randomised trials in non-obese (PROVHILO: ISRCTN70332574) and obese (PROBESE: NCT02148692) patients.